Brand ID element if a droplet icon hyper links to the home page
Contact Us

Our Advisors

The Bethesda Group consultants are comprised of seasoned C-Suite, senior executives with a proven track record of building thriving, sustainable businesses in the molecular diagnostics industry. With a focus on improving patient outcomes, our leaders have successfully guided companies to rapid growth, high-value exits, and delivering above-market shareholder returns.

Bethesda

Partners

Ron Andrews Headshot Teams Page Link to Bio

Ron (Ronnie) Andrews

Founder, Managing Partner

Doug Ross Headshot Teams page

Doug Ross, MD PhD

Chief Scientific Officer

Buzz Sztukowski​

Chief Operating Officer, Managing Partner

Bethesda

Strategic Advisors​

PAUL BILLINGS MD PhD, Chief Scientific Officer

Paul Billings, MD PhD​​

Chief Scientific Officer

RHETT ANDREWS Sr. Analyst & Strategy Consultant

Rhett Andrews​​

Sr. Analyst & Strategy Consultant​​

Ron (Ronnie) Andrews

Founder, Managing Partner

Throughout his distinguished 35-year career in clinical and molecular diagnostics, Ronnie Andrews has demonstrated exceptional leadership across the healthcare spectrum.

Having served as Founding CEO of Clarient (NASDAQ: CLRT) and Oncocyte (NASDAQ: OCX), and held executive positions at industry leaders Abbott Diagnostics, Roche Molecular Diagnostics, Life Technologies, and ThermoFisher, Ronnie brings unparalleled expertise to diagnostic innovation. He has been instrumental in several company exits, delivering above-market returns. His remarkable track record includes mentoring numerous industry CEOs and senior executives, developing a reputation as a trusted advisor who inspires and cultivates the next generation of healthcare leaders.

His talent for developing advanced tools for oncologists and pathologists reflects a sophisticated understanding of both clinical needs and technological possibilities. By seamlessly integrating scientific advancement with business acumen, Ronnie consistently delivers value to organizations poised for growth while furthering the capabilities of precision medicine.

Doug Ross, MD PhD

Chief Scientific Officer

Throughout his distinguished career in medical diagnostics, Dr. Doug Ross has established himself as a visionary at the convergence of genomics, proteomics, and clinical applications.

Having directed sophisticated research and development initiatives at Applied Genomics, Life Technologies, and Oncocyte, Dr. Ross brings unmatched technical expertise to diagnostic assay development. His influential work encompasses creating the diagnostic assays that enhanced Clarient’s acquisition value to GE and leading the pioneering R&D team for Life Technologies’ Oncomine cancer panels, which have become an essential product line for Thermo Fisher.

His talent for developing clinically actionable molecular tests reflects a profound understanding of both genomic complexity and patient-centered care. By seamlessly connecting laboratory innovation with clinical utility, Dr. Ross consistently delivers molecular diagnostic breakthroughs that redefine treatment paradigms while strengthening organizational capabilities in precision medicine.

Doug earned his MD, PhD in pathology from the University of Washington while studying at the Fred Hutchinson Cancer Research Center in Seattle, WA.

EDWARD (BUZZ) SZTUKOWSKI

Managing Partner

With over three decades of strategic execution excellence in healthcare and life sciences, Buzz Sztukowski has built a reputation for transforming corporate vision into measurable market success.

Having guided organizations including Perkin Elmer as President and Biomerieux as General Manager, Buzz delivers exceptional expertise in operational leadership. His extensive executive experience has consistently yielded superior results in business strategy, organizational development, and commercial performance across public and private enterprises.

His methodical approach to value creation stems from deep industry knowledge and disciplined implementation practices. By aligning organizational capabilities with strategic market opportunities, Buzz consistently positions companies for sustainable growth and competitive differentiation in complex healthcare environments

Buzz earned his B.S. in Medical Technology from Fontbonne University and his MBA from the University of Chicago, Booth School of Business.

Paul Billings, MD PhD

Chief Scientific Officer

Throughout his illustrious career at the forefront of genomic medicine, Dr. Paul Billings has demonstrated exceptional leadership in advancing novel genetic technologies from laboratory concept to clinical standard.

Having served in pivotal executive roles including Chief Medical Officer at Laboratory Corporation of America Holdings, Life Technologies, Thermo Fisher Scientific, and Natera, Dr. Billings brings comprehensive expertise to healthcare innovation. His multidimensional impact spans founding ventures, directing public and private companies, advising governmental entities, and mentoring the next generation of medical leaders.

His distinctive talent for identifying clinically valuable genetic markers reflects an intricate understanding of both molecular mechanisms and healthcare delivery systems. By cultivating strategic partnerships between scientific innovators and clinical practitioners, Dr. Billings has repeatedly demonstrated an ability to deliver solutions that enhance diagnostic precision while creating sustainable commercial success.

Paul holds M.D. and Ph.D. degrees in immunology from Harvard University, with postgraduate training at the University of Washington. He is board certified as an internal medicine and medical genetics specialist. He has held academic positions at Harvard, Stanford, and UC San Francisco, where he has mentored the next generation of leaders in genetics and medicine. He has also served on the Advisory Boards at the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS).

Rhett Andrews

Sr. Analyst & Strategy Consultant

As a strategic advisor, Rhett is a results-driven consultant who specializes in identifying growth opportunities, driving value creation, and delivering measurable outcomes for businesses. With a proven track record of success, he has helped clients achieve revenue growth, operational efficiency, and strategic milestones through tailored, data-informed strategies.

Before joining the Bethesda team, Rhett built his career as an M&A and private equity investment banking consultant at pH Blueprint. There, he developed specialized expertise in financial analysis, due diligence, and deal structuring. 

Andrews holds a Bachelor of Science in Finance, from Wofford College.

Contact Us